162 related articles for article (PubMed ID: 10659948)
1. Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform.
Lewis DF; Bird MG; Dickins M; Lake BG; Eddershaw PJ; Tarbit MH; Goldfarb PS
Xenobiotica; 2000 Jan; 30(1):1-25. PubMed ID: 10659948
[TBL] [Abstract][Full Text] [Related]
2. Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1996 Oct; 26(10):1067-86. PubMed ID: 8905920
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.
Lewis DF; Lake BG; George SG; Dickins M; Eddershaw PJ; Tarbit MH; Beresford AP; Goldfarb PS; Guengerich FP
Toxicology; 1999 Nov; 139(1-2):53-79. PubMed ID: 10614688
[TBL] [Abstract][Full Text] [Related]
4. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
Lewis DF
Arch Biochem Biophys; 2003 Jan; 409(1):32-44. PubMed ID: 12464242
[TBL] [Abstract][Full Text] [Related]
5. Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4.
Lewis DF; Lake BG; Dickins M; Eddershaw PJ; Tarbit MH; Goldfarb PS
Xenobiotica; 1999 Apr; 29(4):361-93. PubMed ID: 10375007
[TBL] [Abstract][Full Text] [Related]
6. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
Lewis DF; Eddershaw PJ; Goldfarb PS; Tarbit MH
Xenobiotica; 1997 Apr; 27(4):319-39. PubMed ID: 9149373
[TBL] [Abstract][Full Text] [Related]
7. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives.
Lewis DF; Wiseman A; Tarbit MH
J Enzyme Inhib; 1999; 14(3):175-92. PubMed ID: 10445042
[TBL] [Abstract][Full Text] [Related]
8. The CYP2 family: models, mutants and interactions.
Lewis DF
Xenobiotica; 1998 Jul; 28(7):617-61. PubMed ID: 9711809
[TBL] [Abstract][Full Text] [Related]
9. Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102.
Lewis DF; Lake BG
Xenobiotica; 1999 Aug; 29(8):763-81. PubMed ID: 10553718
[TBL] [Abstract][Full Text] [Related]
10. Molecular modelling of mammalian CYP2B isoforms and their interaction with substrates, inhibitors and redox partners.
Lewis DF; Lake BG
Xenobiotica; 1997 May; 27(5):443-78. PubMed ID: 9179987
[TBL] [Abstract][Full Text] [Related]
11. Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity.
Lewis DF
Exp Toxicol Pathol; 1999 Jul; 51(4-5):369-74. PubMed ID: 10445400
[TBL] [Abstract][Full Text] [Related]
12. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.
Lewis DF
Xenobiotica; 2002 Apr; 32(4):305-23. PubMed ID: 12028664
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure.
Lewis DF; Lee-Robichaud P
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):217-33. PubMed ID: 9744519
[TBL] [Abstract][Full Text] [Related]
14. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity.
Lewis DF; Dickins M; Lake BG; Eddershaw PJ; Tarbit MH; Goldfarb PS
Toxicology; 1999 Mar; 133(1):1-33. PubMed ID: 10413191
[TBL] [Abstract][Full Text] [Related]
15. Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity.
Lewis DF; Bird MG; Parke DV
Toxicology; 1997 Mar; 118(2-3):93-113. PubMed ID: 9129165
[TBL] [Abstract][Full Text] [Related]
16. Molecular modelling of the mouse cytochrome P450 CYP2F2 based on the CYP102 crystal structure template and selective CYP2F2 substrate interactions.
Lewis DF; Bailey PT; Low LK
Drug Metabol Drug Interact; 2002; 19(2):97-113. PubMed ID: 12751909
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ.
Lozano JJ; López-de-Briñas E; Centeno NB; Guigó R; Sanz F
J Comput Aided Mol Des; 1997 Jul; 11(4):395-408. PubMed ID: 9334905
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries.
Lewis DF; Dickins M; Eddershaw PJ; Tarbit MH; Goldfarb PS
Drug Metabol Drug Interact; 1999; 15(1):1-49. PubMed ID: 10707112
[TBL] [Abstract][Full Text] [Related]
19. Homology modelling of the enzyme P450 17 alpha-hydroxylase/17,20-lyase--a target for prostate cancer chemotherapy--from the crystal structure of P450BM-3.
Burke DF; Laughton CA; Neidle S
Anticancer Drug Des; 1997 Mar; 12(2):113-23. PubMed ID: 9113066
[TBL] [Abstract][Full Text] [Related]
20. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
